These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 36122786)

  • 41. Transformations between Co-Amorphous and Co-Crystal Systems and Their Influence on the Formation and Physical Stability of Co-Amorphous Systems.
    Wu W; Wang Y; Löbmann K; Grohganz H; Rades T
    Mol Pharm; 2019 Mar; 16(3):1294-1304. PubMed ID: 30624075
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Novel Desloratadine-Benzoic Acid Co-Amorphous Solid: Preparation, Characterization, and Stability Evaluation.
    Ainurofiq A; Mauludin R; Mudhakir D; Soewandhi SN
    Pharmaceutics; 2018 Jul; 10(3):. PubMed ID: 29986403
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Investigation for the amorphous state of ER-34122, a dual 5-lipoxygenase/cyclooxygenase inhibitor with poor aqueous solubility, in HPMC solid dispersion prepared by the solvent evaporation method.
    Kushida I; Gotoda M
    Drug Dev Ind Pharm; 2013 Oct; 39(10):1582-8. PubMed ID: 22519663
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hydroxypropyl cellulose stabilizes amorphous solid dispersions of the poorly water soluble drug felodipine.
    Sarode AL; Malekar SA; Cote C; Worthen DR
    Carbohydr Polym; 2014 Nov; 112():512-9. PubMed ID: 25129775
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Spray drying of poorly soluble drugs from aqueous arginine solution.
    Ojarinta R; Lerminiaux L; Laitinen R
    Int J Pharm; 2017 Oct; 532(1):289-298. PubMed ID: 28890173
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Co-Amorphous Simvastatin-Nifedipine with Enhanced Solubility for Possible Use in Combination Therapy of Hypertension and Hypercholesterolemia.
    Martínez-Jiménez C; Cruz-Angeles J; Videa M; Martínez LM
    Molecules; 2018 Aug; 23(9):. PubMed ID: 30154310
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Curve-fitting FTIR studies of loratadine/hydroxypropyl-beta-cyclodextrin inclusion complex induced by co-grinding process.
    Lin SY; Hsu CH; Sheu MT
    J Pharm Biomed Anal; 2010 Nov; 53(3):799-803. PubMed ID: 20619996
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interactions Between Paracetamol and Hypromellose in the Solid State.
    Leyk E; Wesolowski M
    Front Pharmacol; 2019; 10():14. PubMed ID: 30740052
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Physicochemical characterization of hot melt extruded bicalutamide-polyvinylpyrrolidone solid dispersions.
    Andrews GP; AbuDiak OA; Jones DS
    J Pharm Sci; 2010 Mar; 99(3):1322-35. PubMed ID: 19798757
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of melt-quenched and milled amorphous solids of gatifloxacin.
    Hattori Y; Suzuki A; Otsuka M
    Drug Dev Ind Pharm; 2016 Nov; 42(11):1851-6. PubMed ID: 27109418
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Amorphous Protic Ionic Systems as Promising Active Pharmaceutical Ingredients: The Case of the Sumatriptan Succinate Drug.
    Wojnarowska Z; Knapik J; Rams-Baron M; Jedrzejowska A; Paczkowska M; Krause A; Cielecka-Piontek J; Jaworska M; Lodowski P; Paluch M
    Mol Pharm; 2016 Mar; 13(3):1111-22. PubMed ID: 26836258
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Highly Soluble Glimepiride and Irbesartan Co-amorphous Formulation with Potential Application in Combination Therapy.
    Cruz-Angeles J; Videa M; Martínez LM
    AAPS PharmSciTech; 2019 Mar; 20(4):144. PubMed ID: 30887140
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Slow dissolution behaviour of amorphous capecitabine.
    Meulenaar J; Beijnen JH; Schellens JH; Nuijen B
    Int J Pharm; 2013 Jan; 441(1-2):213-7. PubMed ID: 23219704
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Stabilization of low glass transition temperature indomethacin formulations: impact of polymer-type and its concentration.
    Chokshi RJ; Shah NH; Sandhu HK; Malick AW; Zia H
    J Pharm Sci; 2008 Jun; 97(6):2286-98. PubMed ID: 17879977
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The development of co-amorphous drug systems].
    Yao J; Shi NQ; Wang XL
    Yao Xue Xue Bao; 2013 May; 48(5):648-54. PubMed ID: 23888685
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Amorphous-state characterization of efavirenz--polymer hot-melt extrusion systems for dissolution enhancement.
    Sathigari SK; Radhakrishnan VK; Davis VA; Parsons DL; Babu RJ
    J Pharm Sci; 2012 Sep; 101(9):3456-64. PubMed ID: 22437488
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A dynamic thermal ATR-FTIR/chemometric approach to the analysis of polymorphic interconversions. Cimetidine as a model drug.
    Calvo NL; Maggio RM; Kaufman TS
    J Pharm Biomed Anal; 2014 Apr; 92():90-7. PubMed ID: 24509287
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Formulation performance and processability window for manufacturing a dual-polymer amorphous solid dispersion via hot-melt extrusion and strand pelletization.
    Hörmann TR; Jäger N; Funke A; Mürb RK; Khinast JG; Paudel A
    Int J Pharm; 2018 Dec; 553(1-2):408-421. PubMed ID: 30326284
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Amorphous-Amorphous Phase Separation in API/Polymer Formulations.
    Luebbert C; Huxoll F; Sadowski G
    Molecules; 2017 Feb; 22(2):. PubMed ID: 28212300
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro and in vivo comparison between crystalline and co-amorphous salts of naproxen-arginine.
    Kasten G; Lobo L; Dengale S; Grohganz H; Rades T; Löbmann K
    Eur J Pharm Biopharm; 2018 Nov; 132():192-199. PubMed ID: 30266670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.